Tarilian Laser Technologies and ViCardio® Very Popular and Successful at MEDICA, Dusseldorf, Germany
Tarilian Laser Technologies (TLT), developer of ViCardio®, the world’s first wearable, beat to beat, non-invasive, accurate and comfortable TLT blood pressure monitor, has completed a very successful show and presentation at the Wearables Chapter of MEDICA (Dusseldorf, Germany) – the world’s largest and most significant Global Medtech Conference.
MEDICA is the worldwide largest medical marketplace. This year more than 5,000 exhibitors presented their innovations to about 130,000 visitors from all over the world, and the TLT and ViCardio® stand at Medical Hall 15 was one of the busiest in the Show.
WT-Wearable Technologies, part of MEDICA, is the pioneer and world leading innovation and market development platform for technologies worn close to the body, on the body and even in the body. Since 2006 the platform has successfully established an ecosystem of more than 30,000 companies comprising market leaders and highly innovative companies.
TLT’s ViCardio® product had also been nominated as MEDICA’s WT Gadget of the Month in October 2018: https://www.wearable-technologies.com/2018/10/october-2018/
Commenting on the success for TLT and ViCardio® at MEDICA 2018, Chief Executive Officer and Co-Founder of TLT & ViCardio, Dr Sandeep Shah, who also delivered a powerful address at the Wearable show on day 1 of the event, stated: “TLT is immensely proud to have its ViCardio® product nominated as MEDICA WT Gadget of the Month in October. We were impressed by the scale of interest at the MEDICA Exhibition into our technology and also the recognition of its unique offering. I had several experts say to me that, in their view, this is the most significant healthcare innovation that they have seen in decades. In all the years that I have attended MEDICA, I have never witnessed and seen such an energy and excitement about the overall future of Medtech and Digital Healthcare – and it is clear that the world has recognised our technology as being part of this future. In addition, we had a large number of distributors and companies across the world inquiring about TLT and ViCardio® and possible partnerships and distribution which will follow the completion of our product registrations.”
Laura Garcia, ViCardio® Marketing Executive commented, “This was my first MEDICA experience, and I was thrilled to see the high interest into our products from many constituencies around the world! We are expecting that this will also increase as our launch approaches!”
Peter Laithwaite, Non-Executive Director of ViCardio Limited, commented, “This was indeed a significant Conference and Exhibition for us and consolidates our view of the positive reception that the TLT ViCardio® medical-grade wearable already enjoys around the world. We are excited that so many people are interested in engaging with us and also becoming potentially becoming future customers once we have formally launched our product following our registration programme!”
Dr Frank Kubik, TLT Asia-Pacific Associate and Medtech Expert, commented, “This was a great experience for us. It clearly demonstrates that that the Medtech and Digital Healthcare markets are hungry for the unique solution that we at TLT have created and one that has been now been also recognised for the positive quality of engineering.”
The ViCardio® device is currently being submitted for European CE mark approval and FDA Clearance. The first thousand devices are anticipated to be available for online purchase in approximately early 2019, following CE marking clearance.
About Tarilian Laser Technologies Limited
Tarilian Laser Technologies Limited (TLT) is a Medtech Company based in Welwyn Garden City, Hertfordshire, UK (Head Office and Labs), as well as having its Vicardio® Commercial office in Leeds, UK and also its US operations office in Minneapolis, Minnesota, USA. TLT is also opening a new regulatory office in Singapore. Our main clinical centre is The Barts Heart Centre in London, Europe’s largest cardiovascular research centre.
Please see: www.tarilian.co.uk to directly access the 30-minute Bloomberg World-Wide Business Interview that summarises TLT and Vicardio®.
TLT is an advanced Medtech SME and is 13485(2016) registered with solid competencies in medical engineering, research & development, clinical trials, regulatory affairs and commercialisation. TLT has developed a novel optical platform based on its internal proprietary patented opto-electronic micro-sensor for full haemodynamic profiling including an ability to generate beat to beat blood pressure, compliance data, cardiac output and regional blood flow and blood pressure. A unique aspect of the TLT Sapphire sensor is that no energy enters the body at all – hence it is truly NON-invasive and also does not require any compression/cuff and or require any calibration in any manner. You simply apply the sensor on the body and it works instantly delivering continuous beat to beat haemodynamic data. The technology has already won many awards and TLT has continued with a number of additional break-throughs in sensor development- and now is planning a series of product launches from Early 2019, to begin the introduction of the technology into a number of international Medtech and consumer wearable markets.
About ViCardio Limited
ViCardio Limited was set up as a commercialisation company by Tarilian Laser Technologies Limited (TLT) in early 2018 with the mission to improve the diagnosis, monitoring and control of blood pressure in the community. The ViCardio® product is TLT’s first wearable blood pressure monitor, powered by TLT’s proprietary optical-electronic micro-motion sensor that allows blood pressure to be measured with each beat of the heart using a simple and elegant wrist-based wearable.
For more information please contact:
Dr Sandeep Shah, CEO of TLT and ViCardio:
Office: +44 (0) 1707 332 883
Laura Garcia, ViCardio Marketing Executive:
Office: +44 (0)3303352277